Return to content in this issue

Presenting prevalence, characteristics and outcome of asthmatic patients with T2 diseases in hospitalized subjects with COVID-19 in Madrid, Spain

Barroso B¹, Valverde-Monge M¹, Cañas JA^2,5, Rodrigo-Muñoz JM^2,5, Gonzalez-Cano B¹, Villalobos-Violan V¹, Betancor D¹, Gomez-Cardeñosa A¹, Vallejo-Chamorro G¹, Baptista L¹, Villalobos-Vilda C¹, Ortega-Martin L¹, Gómez-López A¹, Sanchez-Pernaute O³, Romero-Bueno F³, Rodriguez-Nieto MJ⁴, Del Pozo V^2,5, Sastre J^1,5 and the COVID FJD-TEAM

¹Allergy, Hospital Universitario Fundación Jiménez Díaz and Instituto de Investigación sanitaria (IIS) Fundación Jiménez Díaz, Madrid
²Immunology, Hospital Universitario Fundación Jiménez Díaz and Instituto de Investigación sanitaria (IIS) Fundación Jiménez Díaz, Madrid
³Rheumatology, Hospital Universitario Fundación Jiménez Díaz and Instituto de Investigación sanitaria (IIS) Fundación Jiménez Díaz, Madrid
⁴Pulmunology, Hospital Universitario Fundación Jiménez Díaz and Instituto de Investigación sanitaria (IIS) Fundación Jiménez Díaz, Madrid
⁵CIBER de Enfermedades Respiratorias (CIBERES).

The two first authors contributed equally as first authors.

J Investig Allergol Clin Immunol 2020; Vol. 30(5)
doi: 10.18176/jiaci.0627

• Abstract
• Supplemental Materials

Key words: Asthma, Prevalence, COVID-19, Atopic diseases, SARS-CoV-2, Asthma characterization

	Title	Type	Size
	doi10.1876_jiaci.0627_material-suppl.pdf	pdf	185.01 Kb